Case report: Salivary duct carcinoma in a patient with a germline CDH1 pathogenic variant - expanding the spectrum of hereditary cancer predisposition syndromes

• Published in: Frontiers in oncology Vol. 14; p. 1372382
• Main Authors: Desai, Nidhi, Racila, Emilian, Fujioka, Naomi, Gupta, Arjun, Antonarakis, Emmanuel S
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08-04-2024
• Subjects: cancer; CDH1; germline; Oncology; pathogenic variant; salivary duct carcinoma; cancer; germline; pathogenic variant; CDH1; salivary duct carcinoma
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1372382

Recently, an entity known as salivary duct carcinoma with rhabdoid features (SDC-RF) has been associated with somatic
mutations. Here we present the first known case report of conventional SDC occurring in the setting of a germline
pathogenic variant accompanied by a somatic loss of heterozygosity at the
locus.
A 67-year-old man presented with chest and back pain and was found to have osteolytic lesions in the sternum and lumbar spine. Vertebral bone biopsies were positive for metastatic carcinoma of unknown primary. A molecular profiling assay consisting of both whole-exome next-generation sequencing (NGS) as well as immunohistochemistry (IHC) for select clinically-relevant proteins performed on the bone biopsy suggested a triple-negative (ER/PR/ERBB2 negative, by IHC), androgen receptor (AR IHC) positive tumor profile. Additionally, the assay uncovered a coding mutation in the
gene (c.1792C>T, p.R598*) with genomic loss of the second
allele. Germline testing returned positive for a heterozygous
pathogenic variant. PET-CT revealed a tumor in the neck suggestive of the primary malignancy consistent with that of salivary gland origin. The patient was initially treated with carboplatin and paclitaxel, then pembrolizumab, and finally with AR-directed therapy using leuprolide and enzalutamide. These treatments were not successful, and the patient eventually succumbed to his disease.
Molecular testing revealed that our patient had bi-allelic inactivation of the
gene. We believe our patient developed a somatic mutation in addition to his preexisting germline
mutation that ultimately predisposed him to SDC. While previous studies have found somatic
pathogenic variants in SDC-RF, our patient was found to have a germline
pathogenic variant in the setting of conventional SDC, without rhabdoid features. This case provokes questions regarding tumor genetics and molecular profiling of SDC in patients with germline
pathogenic variants. Moreover, this case supports the notion that SDC may be the salivary counterpart of other malignancies associated with germline
pathogenic variants and may possibly expand the spectrum of tumors that arise in this familial cancer-predisposition syndrome.